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Femoral Artery Atherosclerosis Is Associated With Physical Function
Across the Spectrum of the Ankle-Brachial Index: The San Diego
Population Study
Christina L. Wassel, PhD, MS, FAHA; Alicia M. Ellis, PhD; Natalie C. Suder, MPH; Emma Barinas-Mitchell, PhD; Dena E. Rifkin, MD, MS;
Nketi I. Forbang, MD; Julie O. Denenberg, MA; Antoinette M. Marasco, BS; Belinda J. McQuaide, BS; Nancy S. Jenny, PhD;
Matthew A. Allison, MD, MPH; Joachim H. Ix, MD, MAS; Michael H. Criqui, MD, MPH
Background-—The ankle-brachial index (ABI) is inadequate to detect early-stage atherosclerotic disease, when interventions to
prevent functional decline may be the most effective. We determined associations of femoral artery atherosclerosis with physical
functioning, across the spectrum of the ABI, and within the normal ABI range.
Methods and Results-—In 2007–2011, 1103 multiethnic men and women participated in the San Diego Population Study, and
completed all components of the summary performance score. Using Doppler ultrasound, superficial and common femoral intima
media thickness and plaques were ascertained. Logistic regression was used to assess associations of femoral atherosclerosis
with the summary performance score and its individual components. Models were adjusted for demographics, lifestyle factors,
comorbidities, lipids, and kidney function. In adjusted models, among participants with a normal-range ABI (1.00–1.30), the highest
tertile of superficial intima media thickness was associated with lower odds of a perfect summary performance score of 12 (odds
ratio=0.56 [0.36, 0.87], P=0.009), and lower odds of a 4-m walk score of 4 (0.34 [0.16, 0.73], P=0.006) and chair rise score of 4
(0.56 [0.34, 0.94], P=0.03). Plaque presence (0.53 [0.29, 0.99], P=0.04) and greater total plaque burden (0.61 [0.43, 0.87],
P=0.006) were associated with worse 4-m walk performance in the normal-range ABI group. Higher superficial intima media
thickness was associated with lower summary performance score in all individuals (P=0.02).
Conclusions-—Findings suggest that use of femoral artery atherosclerosis measures may be effective in individuals with a normal-
range ABI, especially, for example, those with diabetes mellitus or a family history of peripheral artery disease, when detection can
lead to earlier intervention to prevent functional declines and improve quality of life. ( J Am Heart Assoc. 2017;6:e005777. DOI:
10.1161/JAHA.117.005777.)
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G lobally, over 200 million people live with peripheralartery disease (PAD),1 with 8.5 million people affected
in the United States alone.2 The associated comorbidities and
surgical procedures because of PAD result in significant cost,
both in terms of quality of life and dollars.3 Of individuals with
PAD, the majority are either asymptomatic (40%) or do not
exhibit classic symptoms of leg claudication (50%), leaving
only 10% who exhibit classic claudication symptoms.4,5 Even
when asymptomatic, PAD is associated with decreased
functional status, mobility, and quality of life, including the
inability to walk one quarter mile, climb 1 flight of stairs, or
complete a 6-minute walk.6
In population-based studies including those with and
without PAD (ankle-brachial index [ABI] ≤0.90), the ABI has
been associated with measures of functional status and
physical function,7–9 as well as declines in physical function
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over time.10 However, the ABI is inadequate for detecting
early-stage lower extremity atherosclerotic disease, when
intervention efforts to prevent functional decline, associated
comorbid conditions, and mitigate the high risk of mortality,
may be most effective. By the time ABI progresses into the
abnormal range (≤0.90), significant lower extremity disease is
typically present11 (ie, stenosis >50%), providing less oppor-
tunity for effective intervention.
Among individuals with PAD, the presence and character-
istics of superficial femoral artery plaques have been asso-
ciated with poorer physical function,12,13 even after
adjustment for levels of the ABI. However, femoral artery
measures of atherosclerosis could also provide a path to
earlier intervention in individuals without PAD and a normal
range (ie, 1.00–1.30) or borderline (0.91–0.99) ABI, especially
among those with a normal ABI and significant comorbidities
or family history of PAD, or in detection of those with
asymptomatic PAD. This in turn could lead to prevention of
functional decline and improved quality of life.
In a population-based, multiethnic cohort of men
and women, we examined the associations of common and
superficial femoral artery intima media thickness (IMT) and
atherosclerotic plaque presence and frequency with the
summary performance score (SPS) and its components,
across the range of the ABI, as well as in a subset with a
normal-range ABI. Additionally, as inflammation and coagula-
tion play a significant role in lower extremity subclinical
atherosclerosis,14–18 we determined whether circulating
levels of inflammation and coagulation markers mediated
the associations of femoral artery atherosclerosis and the
SPS.
Methods
Study Participants
The San Diego Population Study is a prospective cohort of
ethnically diverse men and women designed to study lower
extremity PAD and venous disease. The follow-up examination
took place from 2007 to 2011, when 1103 participants
returned an average of 11 years after their first clinical
examinations in 1994–1998. Participants were current or
former employees of the University of California—San Diego
or significant others of these employees, who resided in San
Diego County. Participants were then chosen randomly within
age, race/ethnic and sex strata, resulting in the cohort of
65% women, and 60% non-Hispanic white, 13% black, 15%
Hispanic, and 12% Asian. Women and racial/ethnic minorities
(black, Hispanic, Asian) were oversampled in order to have
adequate power for hypotheses involving these groups. The
current study includes the 1103 participants from the follow-
up examination in 2007–2011. Further details of the study
have been published elsewhere.19–21
For all study procedures, participants provided signed
informed consent after a detailed introduction and description
of the study at both the baseline and follow-up examinations.
The study received approval from the Institutional Review
Board Committee on Investigations Involving Human Subjects
at University of California-San Diego.
Ankle-brachial index
With the participant in a supine position, systolic blood
pressure was measured twice in both arms. Continuous-wave
Doppler ultrasound (Acuson Aspen, Seimens, Inc) was used to
measure systolic blood pressure twice in both the anterior
and posterior tibial arteries. The ABI for each side was
calculated as the maximum of the average systolic blood
pressure of the posterior tibial or dorsalis pedis divided by the
maximum of the average of the left and right arm systolic
blood pressure. The higher arm systolic blood pressure was
Clinical Perspective
What Is New?
• In a multiethnic population-based study of predominantly
healthy older men and women, presence of femoral artery
atherosclerosis was significantly associated with worse
physical function, extending previous findings in those with
peripheral artery disease.
• Even among participants with a normal-range ankle-brachial
index (1.00–1.30), higher levels of the superficial femoral
artery intima media thickness and plaque presence were
significantly associated with worse physical performance.
• Associations of femoral artery atherosclerosis and physical
function did not appear to be mediated by inflammatory or
coagulation biomarkers in this study.
What Are the Clinical Implications?
• Findings suggest that even early stages of femoral artery
atherosclerosis are associated with changes in physical
performance.
• While it may be prohibitive to screen all patients with a
normal ankle-brachial index for femoral atherosclerosis, it
could be beneficial for early detection in individuals with a
normal ankle-brachial index and other comorbidities such as
type 2 diabetes mellitus or a family history of peripheral
artery disease.
• Femoral artery atherosclerosis measures may be especially
effective in those who have a normal-range ankle-brachial
index and who are likely asymptomatic, when detection can
lead to earlier intervention (ie, lifestyle changes or initiation
or intensification of statin treatment), to prevent functional
declines.
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used in these calculations because of previous studies
showing a strong association between PAD and subclavian
stenosis.22 The overall ABI was defined as the lower of the left
and right ABI.
Femoral Artery Atherosclerosis
Doppler ultrasound (Acuson Aspen, Seimens, Inc) was used to
image the left and right superficial and common femoral
arteries in 10-mm segments at an angle of insonation of 90
degrees. Two segments each on the left and right legs were
obtained: (1) at the common femoral artery as it emerged
from under the inguinal ligament proximal to its bifurcation
into the profunda and superficial femoral branches, and (2) at
the superficial femoral artery distal to the bifurcation.
Carotid Analyzer software from the Vascular Research
Tools 5 Suite (Medical Imaging Applications, LLC, Coralville,
IA) was used by trained ultrasound technicians to measure the
IMT, as well as to determine plaque presence and frequency.
Quality control monitoring was performed at regular intervals
throughout the study, using the ultrasound images from 10 to
20 participants. Both inter- and intrareader intraclass corre-
lations generally were >80% for common femoral IMT, and
>75% for superficial femoral IMT. In particular, intrareader
intraclass correlations were >95% for both the superficial and
common femoral IMTs. Spearman correlations for both inter-
and intrareader were >0.89 for common femoral IMT, and
>0.70 for superficial femoral IMT.
As the far (posterior) arterial wall provided the best images
with the least amount of noise, the common and superficial
femoral IMTs were calculated as the average of the far wall of
both the left and right leg femoral arteries to ensure the
lowest possible measurement error. IMTs were calculated
even when plaque was present in the segment. Plaque
presence was defined by the Mannheim consensus as a focal
structure encroaching into the arterial lumen at least
0.50 mm or 50% greater thickness relative to the surrounding
IMT, or thickness >1.5 mm as measured from the media-
adventitia border to the intima-lumen border.23,24 For some
arterial segments, clear visualization of plaques was limited
because of the presence of artifact, and these plaques were
classified as probable plaques. Otherwise, participants were
classified as having a definite plaque or no visible plaque.
Summary Performance Score
Participants completed the 3 component measures of the
SPS, including time to rise from a seated position 5 times, the
standing balance, and usual 4-m walking velocity.25 Each
component was scored from 0 and 4; a 0 on a component
corresponds to an inability to complete that component, while
a 4 corresponds to the best performance. The 3 component
scores were summed to calculate the overall SPS, which
ranged from 0 to 12. The scale was derived from normative
data in 6534 community-dwelling older men and women
participating in the Established Populations for the Epidemi-
ologic Study of the Elderly.25
Covariates
Age, sex, race/ethnicity, presence of osteoarthritis, and
current and past cigarette smoking habits were ascertained
via questionnaire. Smoking was defined as ever having
smoked versus never smoked. Height (in centimeters) and
weight (in kilograms) were measured, and the body mass
index was calculated as kg/m2. A medication inventory was
conducted to obtain information on a variety of medications,
including statins, as well as diabetes mellitus or hypertension
medication use. Diabetes mellitus was defined as self-report,
or use of antidiabetic medications or insulin. Systolic and
diastolic blood pressures were measured in the right arm for
each participant after 5 minutes of rest. Hypertension was
defined as a systolic pressure ≥140 mm Hg or a diastolic
pressure ≥90 mm Hg, or use of antihypertensive medica-
tions. Cardiovascular disease, including previous myocardial
infarction, stroke, angioplasty, or revascularization, was also
assessed via self-report questionnaire.
Nonfasting blood samples were collected, stored at
80°C, and transferred to a laboratory where they were
analyzed within 24 hours. Direct enzymatic assays were used
to determine total and high-density lipoprotein cholesterol on
the Roche Cobas 6000 analyzer (Roche Diagnostics Corpo-
ration, Indianapolis, IN).26 Low-density lipoprotein cholesterol
was estimated using the Friedewald equation.27 Dyslipidemia
was defined as a ratio of total cholesterol to high-density
lipoprotein cholesterol >5.0 or statin use, which has consis-
tently been found the best single lipid/lipoprotein parameter
in assessing cardiovascular disease risk,28 or use of lipid-
lowering medications at baseline. Serum creatinine levels
were calibrated to the isotope dilution mass spectrometry
standard and measured using a Roche Cobas 6000 analyzer
(Roche Diagnostics Corporation, Indianapolis, IN). Estimated
glomerular filtration rate was calculated with the CKD-Epi
equation.29
Inflammation and Coagulation Markers
C-reactive protein (CRP) and fibrinogen were measured in
EDTA plasma, and lipoprotein-a was measured in serum, using
nephelometric assays on a BNII System (Siemens Healthcare,
Erlange, Germany). The ranges of interassay coefficients of
variation for CRP, fibrinogen, and lipoprotein-a were 4.1% to
5.1%, 3.2% to 4.7%, and 5.2% to 8.2%, respectively. Intercel-
lular adhesion molecule-1 and pentraxin-3 were measured in
DOI: 10.1161/JAHA.117.005777 Journal of the American Heart Association 3
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EDTA plasma using ELISA (R&D Systems, Minneapolis, MN),
with coefficient of variation ranges of 10.3% to 11.0% and
9.3% to 14.9%, respectively. Intercellular adhesion molecule-1
was measured using a nonallele-specific assay. Interleukin
(IL)-6 was measured in serum, also via ELISA (R&D Systems,
Minneapolis, MN), with a coefficient of variation range of 4.2%
to 6.3%. D-dimer was measured in EDTA plasma on the
Evolution Coagulation Analyzer (Diagnostica Stago, Parsip-
pany, NJ), with a coefficient of variation range of 2.7% to
24.7%.
Statistical Analysis
Univariate associations of superficial femoral artery IMT
tertiles and participant characteristics were conducted using
ANOVA, v2, or Kruskal–Wallis as appropriate. Superficial and
common femoral artery IMT were modeled both as continuous
per SD, as well as tertiles. Any plaque presence was defined
as participants with definite or probable plaques versus no
plaques in any 1 of the 4 arterial segments: left superficial,
right superficial, left common or right common femoral
arteries. Total number of plaques (definite+probable plaques)
was obtained by summing the number of plaques across the 4
arterial segments, and modeled as a continuous variable.
Because of the large proportion of participants with a perfect
score of 12 (73%), SPS was modeled as a binary outcome (12
versus <12). Logistic regression was employed to examine
the association of each femoral artery atherosclerosis mea-
sure separately with the SPS, with staged model adjustment
to determine potential confounders. Final models were
adjusted for age, sex, race/ethnicity, body mass index, ever
smoking, hypertension, diabetes mellitus, estimated glomeru-
lar filtration rate, dyslipidemia, osteoarthritis, and cardiovas-
cular disease. Additionally, separate analyses were also
performed using logistic regression, for the 3 SPS subscales
(chair rises, standing balance, and 4-m walk), with 4 versus <4
as the binary outcomes. Analyses were conducted among all
participants, and also stratified by ABI categories. Participants
with symptomatic PAD (ie, with a previous leg angioplasty or
revascularization at either the baseline or follow-up examina-
tions) were excluded from analyses including normal or
borderline range ABI groups, regardless of their postproce-
dure ABI.
To determine whether inflammation and coagulation
biomarkers mediated the associations between femoral artery
atherosclerosis measures and the SPS, analyses were
conducted using the mediate function in the mediation
package in R Version 3.3.1 following the methods described
by Imai et al30 for linear and nonlinear relationships. CRP,
fibrinogen, IL-6, pentraxin-3, lipoprotein-a, D-dimer, and
intercellular adhesion molecule-1 were modeled as continu-
ous variables and each was considered separately as
mediating factors. Models were adjusted for age, sex, and
race/ethnicity, as well as these demographics plus body mass
index, ever smoking, hypertension, diabetes mellitus, esti-
mated glomerular filtration rate, dyslipidemia, osteoarthritis,
and cardiovascular disease.
Results
A total of 1062 participants had available data on the
superficial femoral artery, and 1021 had available data on the
common femoral artery, while plaque presence was available
on 1065. The meanSD for superficial femoral IMT was
0.590.12 mm and 0.870.46 mm for the common femoral
segment. Approximately 26% (273/1065) of participants had
plaque present, with a meanSD number of plaques across
all segments of 0.390.76. The overall average SPS was
11.21.9, with 73% of participants having a perfect SPS of
12.
Participants differed significantly across tertiles of super-
ficial femoral artery IMT in all traditional cardiovascular risk
factors with the exceptions of low-density lipoprotein choles-
terol, diastolic blood pressure, and diabetes mellitus
(Table 1). Additionally, participants only marginally differed
with regard to the continuous ABI across tertiles of superficial
femoral IMT (P=0.11); however, the univariate association of
ABI categories with superficial femoral IMT tertiles was
significant (P=0.001). Participants also had higher levels of
IL-6 (P<0.001) and pentraxin-3 (P=0.01) with increasing tertile
of superficial femoral IMT, but did not differ significantly for
the other markers of inflammation or coagulation (Table 1).
Figure 1 displays the average superficial and common
femoral IMT, as well as average number of plaques by femoral
artery segment across ABI categories. Common femoral IMT
and mean number of plaques have a distinct U-shaped
relationship across ABI categories. Compared to the low
(≤0.90) and high (>1.30) ABI categories, superficial femoral
IMT was decreased somewhat in the borderline and normal
ABI categories (0.91–0.99 and 1.00–1.30). Number of
superficial femoral plaques also shows a U-shaped relation-
ship across ABI categories, but this was less pronounced than
for common femoral IMT and plaques.
In models adjusted for demographic, lifestyle, and comor-
bid conditions, each SD greater superficial femoral IMT was
associated with significantly lower odds (odds ratio=0.82,
95% CI [0.69, 0.97], P=0.02) of having a perfect SPS of 12
(Table 2). These results were similar when restricting the
range of the ABI to 0.91 to 1.40 or 1.00 to 1.30. Further,
participants in the highest tertile of superficial femoral IMT
(≥0.61 mm) had much lower odds (0.56 [0.38–0.84],
P=0.005) of having a perfect SPS of 12, compared with
those in the lowest tertile (0.24–0.56 mm) of the superficial
DOI: 10.1161/JAHA.117.005777 Journal of the American Heart Association 4
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femoral IMT. This was similar across the whole range of the
ABI, and also when restricting to the normal range of the ABI
(Table 2). However, there was no significant association with
the overall SPS regarding the common femoral IMT, plaque
presence, or plaque number (Table 2). The continuous ABI
across the whole range was not significantly associated with a
Table 1. Participant Characteristics by Tertiles of Superficial Femoral IMT
Tertile 1
≤0.555 mm
Tertile 2
0.556 to 0.608 mm
Tertile 3
>0.608 mm P Value
Age, y* 689 7110 7310 <0.001
Female sex† 289 (79%) 245 (70%) 176 (51%) <0.001
Race/ethnicity†
Non-Hispanic white 206 (56%) 217 (62%) 222 (64%) 0.04
Black 57 (16%) 46 (13%) 50 (14%)
Hispanic 44 (12%) 38 (11%) 48 (14%)
Asian 58 (16%) 48 (14%) 28 (8%)
Ever smoker† 116 (32%) 100 (29%) 139 (40%) 0.005
Body mass index, kg/m2* 265 275 286 <0.001
Systolic BP, mm Hg* 12719 13119 13418 <0.001
Diastolic BP, mm Hg* 7410 7610 7511 0.23
HDL cholesterol, mg/dL* 6522 6019 5621 <0.001
LDL cholesterol, mg/dL* 11132 10933 10939 0.62
Estimated GFR, min/mL per 1.73 m2* 8117 7716 7619 <0.001
Osteoarthritis† 82 (23%) 100 (29%) 74 (22%) 0.07
Hypertension†,‡ 180 (49%) 223 (64%) 260 (75%) <0.001
Diabetes mellitus†,‡ 29 (8%) 33 (10%) 45 (13%) 0.08
Dyslipidemia†,‡ 131 (36%) 147 (42%) 154 (44%) 0.06
Statin use† 99 (28%) 123 (36%) 118 (35%) 0.06
Cardiovascular disease†,‡ 19 (5%) 34 (10%) 40 (12%) 0.009
ABI* 1.130.12 1.150.17 1.140.21 0.11
ABI categories†
≤0.90 7 (2%) 7 (2%) 18 (5%) 0.001
0.91 to 0.99 14 (4%) 12 (4%) 21 (6%)
1.00 to 1.30 338 (93%) 309 (90%) 286 (83%)
>1.30 4 (1%) 15 (4%) 18 (5%)
C-reactive protein, mg/L§ 0.94 (0.49, 2.31) 1.14 (0.52, 2.79) 1.24 (0.63, 2.33) 0.09
Interleukin-6, pg/mL§ 1.64 (1.01, 2.41) 1.83 (1.22, 2.95) 2.04 (1.39, 2.97) <0.001
D-dimer, lg/mL§ 0.37 (0.23, 0.64) 0.40 (0.23, 0.71) 0.42 (0.26, 0.75) 0.07
Fibrinogen, mg/dL§ 380 (329, 430) 380 (340, 428) 387 (337, 433) 0.70
ICAM-1, ng/mL§ 334 (283, 415) 344 (286, 415) 355 (298, 420) 0.13
Lipoprotein-a, g/L§ 0.11 (0.04, 0.33) 0.11 (0.05, 0.33) 0.13 (0.04, 0.38) 0.72
Pentraxin-3, ng/mL§ 1.25 (0.81, 1.90) 1.21 (0.80, 1.69) 1.36 (0.96, 1.94) 0.01
Diabetes mellitus was defined as self-report, or use of antidiabetic medications or insulin. Dyslipidemia was defined as a ratio of total cholesterol to high-density lipoprotein cholesterol
(TC/HDL) >5.0 or statin use. Cardiovascular disease was defined as self-report of previous myocardial infarction, stroke, angioplasty, or revascularization. ABI indicates ankle-brachial
index; BP, blood pressure; IMT, intima media thickness; GFR, glomerular filtration rate; ICAM-1, intercellular adhesion molecule-1; HDL, high-density lipoprotein; LDL, low-density lipoprotein
*MeanSD; ANOVA used.
†n (%); v2 test used.
‡Hypertension was defined as a systolic pressure ≥140 mm Hg or a diastolic pressure ≥90 mm Hg, or use of antihypertensive medications.
§Median (Q1, Q3); Kruskal–Wallis test used.
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lower odds of an SPS equal to 12 (P=0.72), or when
restricting the ABI to 0.91 to 1.40 (P=0.79) or 1.00 to 1.30
(P=0.87).
Among participants with a normal range ABI (1.00–1.30),
of the 3 separate components of the SPS (chair rises,
standing balance, and 4-m walk), the superficial femoral IMT
appeared to exhibit the strongest association with the 4-m
walk test (Table 3). Specifically, each SD higher superficial
femoral IMT was associated with a significantly lower odds of
a perfect score on the 4-m walk (P=0.001). Moreover,
participants in the highest tertile of the superficial femoral
IMT had a 0.34-fold lower odds of a perfect score on the 4-m
walk (P=0.006). These associations were similar, although
less strong, for chair rises (Table 3). Additionally, associations
of common femoral IMT with the 4-m walk score were
marginally significant; participants in tertiles 2 (0.68–
0.82 mm) and 3 (>0.82 mm) had approximately half the
odds of a perfect 4-m walk score (Table 3), P=0.11, P=0.08,
respectively. Among those with a normal ABI (1.00–1.30),
participants with any femoral plaque had roughly half the odds
(P=0.04) of a perfect 4-m walk score compared with those
with no plaques, and each additional plaque corresponded to
a 0.61-fold lower odds (P=0.006) of a perfect 4-m walk score
(Table 3).
In sensitivity analyses, we modeled plaque presence and
total number of plaques with categorization as definite versus
probable/no plaque, and results were similar to those in
Tables 2 and 3 (data not shown). Additionally, we examined
the SPS as a continuous outcome using ANOVA/linear
regression, again with similar results (data not shown).
Figure 1. Femoral artery intima media thickness and plaques by
ankle-brachial index categories. This figure displays the mean
number of plaques (superficial or common femoral) or the mean
intima media thickness (superficial and common femoral artery)
on the y-axis by categories of the ankle-brachial index on the
x-axis. Blue bars represent the superficial femoral IMT, red bars
represent the common femoral IMT, green bars represent
common femoral artery plaques, and purple bars represent
superficial femoral artery plaques. IMT indicates intima media
thickness.
Table 2. Associations of Femoral Artery IMT and Plaques With SPS*
SPS, 12 vs <12
All Participants, n=1049
OR (95% CI); P Value
SPS, 12 vs <12
0.90 < ABI ≤1.40, n=997
OR (95% CI); P Value
SPS, 12 vs <12
1.00 ≤ ABI ≤1.30, n=933
OR (95% CI); P Value
Common femoral IMT per SD 0.92 (0.80, 1.06); 0.26 0.90 (0.75, 1.07); 0.23 0.90 (0.75, 1.08); 0.25
Superficial femoral IMT per SD 0.82 (0.69, 0.97); 0.02 0.82 (0.67, 0.99); 0.04 0.82 (0.67, 1.01); 0.05
Common femoral IMT
Tertile 1 Ref Ref Ref
Tertile 2 0.75 (0.1, 1.11); 0.15 0.73 (0.49, 1.09); 0.13 0.76 (0.50, 1.15); 0.20
Tertile 3 0.85 (0.57, 1.27); 0.43 0.83 (0.55, 1.25); 0.38 0.89 (0.58, 1.37); 0.59
Superficial femoral IMT
Tertile 1 Ref Ref Ref
Tertile 2 0.80 (0.57, 1.22); 0.34 0.84 (0.56, 1.25); 0.13 0.83 (0.55, 1.25); 0.38
Tertile 3 0.56 (0.38, 0.84); 0.005 0.56 (0.37, 0.84); 0.006 0.56 (0.36, 0.87); 0.009
Plaque presence† 0.86 (0.61, 1.22); 0.40 0.85 (0.59, 1.22); 0.38 0.82 (0.56, 1.21); 0.32
Plaque number‡ 0.90 (0.74, 1.09); 0.26 0.88 (0.71, 1.11); 0.29 0.84 (0.66, 1.07); 0.16
ABI 1.03 (0.89, 1.20); 0.71 1.05 (0.75, 1.47); 0.79 0.97 (0.63, 1.47); 0.87
*Models adjusted for age, sex, race/ethnicity, BMI, ever smoking, hypertension, diabetes mellitus, estimated glomerular filtration rate, dyslipidemia, osteoarthritis, and cardiovascular
disease. ABI, ankle-brachial index; BMI, body mass index; IMT, intima media thickness; OR, odds ratio; SPS, summary performance score
†Plaque presence in any 1 of the following arterial beds: left or right superficial femoral, left or right common femoral.
‡Summed over all 4 arterial beds: left and right superficial femoral, left and right common femoral.
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In demographic-adjusted analyses, IL-6 appeared to sig-
nificantly mediate the association of superficial femoral IMT
and SPS, as well as components of SPS (Figure 2). This held
for analyses among all participants as well as restricted to
participants with a normal ABI (1.00–1.30). However, in
models adjusted for demographics, lifestyle, and comorbid
conditions, IL-6 no longer appeared to be a mediator. In fully
adjusted models, among all participants, CRP had marginal
significance as a mediator for SPS (P=0.07), standing balance
(P=0.08), and was significant for the 4-m walk (P=0.04)
(Figure 2). Among those with a normal ABI, in fully adjusted
models, CRP had marginal significance as a mediator for the
SPS (P=0.12) and the 4-m walk (P=0.10) (Figure 2). Addi-
tionally, among those with a normal ABI in fully adjusted
models, pentraxin-3 was marginally significant as a mediator
for chair rises (P=0.09) (Figure 2). Mediation results for the
associations of plaque presence and plaque number with the
SPS followed similar patterns (data not shown). Mediation
analyses with common femoral IMT were not conducted since
the associations with SPS were not statistically significant
either overall or in any of the ABI subgroups.
Discussion
In a multiethnic population-based study of predominantly
healthy older men and women, we demonstrate that femoral
artery atherosclerosis assessed by ultrasound is associated
with poorer physical performance, extending previous findings
in participants with PAD.12,13 Across the whole range of the
ABI, higher superficial femoral IMT was significantly associ-
ated with worse physical performance. Associations of the
common femoral IMT with SPS were suggestive based on the
magnitudes of the effect, but not statistically significant. Even
among participants with a normal-range ABI (1.00–1.30), the
highest tertile of superficial IMT remained significantly
associated with worse physical performance. Additionally,
we observed a U-shaped relationship of IMT and plaques
across ABI categories. This is especially of interest for the
highest ABI category (>1.30): PAD or subclinical PAD is
present at an increased rate in this group, and can be
successfully detected in participants with high ABI or
incompressible arteries (indicating arterial stiffness) using
measures of femoral artery atherosclerosis instead of the ABI.
This suggests that atherosclerotic disease, along with arterial
stiffness, could be responsible for the increased risk of
cardiovascular disease events observed among those with a
high ABI.
Further examination of individual SPS components among
participants with a normal ABI showed this association was
largely driven by associations of higher superficial IMT with
worse 4-m walk and chair rise performance. Additionally, both
any plaque presence and greater total plaque burden across
the superficial and common femoral arteries were significantly
associated with worse performance on the 4-m walk in the
normal ABI group. Collectively, these data demonstrate that
femoral artery ultrasound measures of atherosclerosis are
Table 3. Associations of Femoral Artery IMT and Plaques With SPS Components Among Participants With a Normal-Range ABI*
Chair Rises, 4 vs <4
OR (95% CI); P Value
Standing Balance, 4 vs <4
OR (95% CI); P Value
4-m Walk, 4 vs <4
OR (95% CI); P Value
Common femoral IMT per SD 1.01 (0.82, 1.24); 0.93 0.96 (0.77, 1.19); 0.70 0.87 (0.67, 1.13); 0.31
Superficial femoral IMT per SD 0.83 (0.66, 1.04); 0.09 0.90 (0.70, 1.15); 0.38 0.65 (0.51, 0.83); 0.001
Common femoral IMT
Tertile 1 Ref Ref Ref
Tertile 2 0.89 (0.55, 1.42); 0.62 0.82 (0.44, 1.54); 0.54 0.55 (0.27, 1.14); 0.11
Tertile 3 1.25 (0.76, 2.07); 0.38 1.12 (0.60, 2.09); 0.73 0.52 (0.24, 1.09); 0.08
Superficial femoral IMT
Tertile 1 Ref Ref Ref
Tertile 2 0.74 (0.46, 1.20); 0.23 0.63 (0.34, 1.17); 0.14 0.63 (0.30, 1.34); 0.23
Tertile 3 0.56 (0.34, 0.94); 0.03 0.52 (0.27, 0.98); 0.04 0.34 (0.16, 0.73); 0.006
Plaque presence† 0.87 (0.56, 1.35); 0.52 1.01 (0.60, 1.70); 0.97 0.53 (0.29, 0.99); 0.04
Plaque number‡ 0.81 (0.62, 1.06); 0.12 1.01 (0.73, 1.38); 0.98 0.61 (0.43, 0.87); 0.006
ABI indicates ankle-brachial index; BMI, body mass index; IMT, intima media thickness; OR, odds ratio; SPS, summary performance score.
*Among those with 1.00 ≤ ABI ≤1.30 (n=933); models adjusted for age, sex, race/ethnicity, BMI, ever smoking, hypertension, diabetes mellitus, estimated glomerular filtration rate,
dyslipidemia, osteoarthritis, and cardiovascular disease.
†Plaque presence in any 1 of the following arterial beds: left or right superficial femoral, left or right common femoral.
‡Summed over all 4 arterial beds: left and right superficial femoral, left and right common femoral.
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associated with worse physical performance even among
persons with normal-range ABI measurements.
In a previous study among 457 participants with PAD, the
presence of a superficial femoral artery obstruction was
significantly associated with worse 6-minute walk time, slower
velocity on the 4-m walk, and a lower score on the short
physical performance battery.13 The short physical perfor-
mance battery is the same scale as the SPS used in our study.
Higher mean superficial femoral plaque area has also been
shown to be significantly associated with poorer 6-minute
walk time and slower walking velocity12 in a separate study of
454 participants with PAD. Even after adjustment for the ABI,
the associations of presence and characteristics of superficial
femoral plaques with poorer physical function remained
significant in both of these studies.12,13 The current study
extends these findings to a population-based study and shows
that superficial femoral artery IMT, as well as plaque presence
and burden, are important determinants of physical
functioning even among relatively healthy older adults with
a normal-range ABI.
The inconsistencies in the strength of associations
between superficial and common femoral atherosclerosis
could be possibly because of larger plaques creating worse
stenosis in the superficial femoral artery, which in turn could
lead to a lower level of physical functioning. Or, any amount of
obstruction in the superficial femoral artery may result in a
greater effect on physical functioning compared with plaque
presence or a similar plaque burden in the common femoral
artery. Anatomically, the superficial femoral artery feeds into
the popliteal artery, and the superficial femoral is one of the
most common sites of lower extremity atherosclerosis.31,32
Additionally, the common femoral artery supplies blood to the
thigh muscles while the superficial femoral artery supplies
blood to calf muscles. Thus, superficial femoral artery
obstruction may have a greater impact on any early declines
in physical functioning, particularly for the 4-m walk or chair
A
SPS
Chair 
Rises
Standing 
Balance
Four Meter 
Walk
SPS
Chair 
Rises
Standing 
Balance
Four Meter 
Walk
Interleukin-6 (pg/mL) 0.002 0.01 0.002 0.005 0.004 0.01 0.01 0.08 p=1
C-reacve Protein (mg/L) 0.13 0.18 0.12 0.12 0.52 0.60 0.59 0.56
ICAM-1 (ng/mL) 0.59 0.56 0.58 0.87 0.16 0.13 0.18 0.83
Pentraxin-3 (ng/mL) 0.81 0.74 0.77 0.89 0.18 0.17 0.18 0.80 p=0.50
Fibrinogen (mg/dL) 0.41 0.35 0.43 0.51 0.69 0.67 0.84 0.95
D-dimer (ug/mL) 0.42 0.45 0.48 0.95 0.87 0.88 0.88 0.90
Lp(a) 0.96 0.93 1.00 0.98 0.87 0.85 0.88 0.91
p<0.01
B
SPS
Chair 
Rises
Standing 
Balance
Four Meter 
Walk
SPS
Chair 
Rises
Standing 
Balance
Four Meter 
Walk
Interleukin-6 (pg/mL) 0.21 0.21 0.20 0.23 0.22 0.22 0.20 0.25
C-reacve Protein (mg/L) 0.07 0.29 0.08 0.04 0.12 0.44 0.27 0.10
ICAM-1 (ng/mL) 0.95 0.99 0.94 0.94 0.33 0.27 0.32 0.99
Pentraxin-3 (ng/mL) 0.64 0.63 0.61 0.83 0.13 0.09 0.14 0.69
Fibrinogen (mg/dL) 0.28 0.05 0.48 0.32 0.66 0.13 0.85 0.87
D-dimer (ug/mL) 0.38 0.37 0.40 0.87 0.75 0.74 0.83 0.94
Lp(a) 0.97 0.97 0.98 0.93 0.83 0.82 0.91 0.99
All Individuals Among 1.00≤ABI≤1.30
All Individuals Among 1.00≤ABI≤1.30
Figure 2. Mediation of the superficial femoral intima media thickness and summary performance score associations by inflammatory and
coagulation markers. A, Models adjusted for age, sex, and race/ethnicity, among all participants and those with a normal-range ABI (1.00–1.30).
B, Models adjusted for age, sex, race/ethnicity, BMI, ever smoking, hypertension, diabetes mellitus, estimated glomerular filtration rate,
dyslipidemia, osteoarthritis, and cardiovascular disease, among all participants and those with a normal-range ABI (1.00–1.30). This figure
shows mediation effects of inflammation and coagulation markers on the superficial femoral IMT and SPS among all participants and among
those with a normal-range ABI for different levels of model adjustment (A and B). Each cell color represents the significance level of the P value,
and P values are noted in text in each box. P values are for the mediation effect of each individual inflammation or coagulation marker on the
superficial femoral IMT and SPS (or individual components). ABI indicates ankle-brachial index; BMI, body mass index; ICAM-1, intercellular
adhesion molecule-1; IMT, intima media thickness; Lp(a), lipoprotein a; SPS, summary performance score.
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rises, which are tests likely more dependent upon the calf
musculature. For the 4-m walk, among participants with a
normal-range ABI, we did observe concordant results in
magnitude and direction between the superficial and common
femoral IMT, albeit with marginal statistical associations for
the common femoral IMT.
Inflammation and coagulation play a significant role in the
atherosclerotic process and have previously been associated
with femoral artery atherosclerosis.14–18 However, in our
study, after adjustment for demographics, lifestyle factors,
and comorbid conditions, none of the inflammatory or
coagulation markers appeared to be mediators of the femoral
artery atherosclerosis and physical function associations.
This held for both the whole range of the ABI and in the
normal ABI group. In this regard, IL-6 does appear to be
consistently associated with subclinical lower extremity
atherosclerosis in both population-based studies and clinical
samples with more severe lower extremity atherosclerotic
disease.17,18 This is partially supported by the mediation
findings in our study, with IL-6 showing the most significant
mediation effects in minimally adjusted models. However,
upon further adjustment, IL-6 no longer appeared to be a
mediator, indicating that the inflammation burden associated
with other risk factors such as hypertension, diabetes
mellitus, ever smoking, and dyslipidemia also contributes to
the pathways between lower extremity atherosclerosis and
physical function. It may also be that inflammation and
coagulation have the most significant impacts, and are at
their highest circulating levels, resulting in the highest
inflammatory burden, in the latter stages of lower extremity
atherosclerotic disease. These effects may not have been
detected in the current study because the San Diego
Population Study comprises largely healthy older adults, with
a smaller proportion of PAD cases than a clinical sample
might include.
A low ABI, a major clinical diagnostic criterion for PAD for
over 40 years, has been associated with worse functional
performance and status7,9 and declines in physical function
over time10 in population-based studies. Our findings suggest,
however, that the ABI may be insensitive for detecting early-
stage lower extremity atherosclerotic disease. By the time the
ABI progresses towards and below 0.90, hemodynamically
significant fixed stenotic lesions are usually present (ie,
stenosis >50%).11 Flanigan et al reported that femoral artery
ultrasound showed significant improvements in sensitivity
compared with the ABI in detecting the presence of lower
extremity atherosclerosis.33 Additionally, use of femoral artery
atherosclerosis measures may aid in cardiovascular risk
stratification, even in low-risk individuals.34 Taken together,
this suggests that the superficial femoral artery for
atherosclerosis may be superior to the ABI for successful,
early identification of individuals with lower extremity disease,
when intervention efforts to prevent disease progression and
functional decline might be most effective.
Our study has several strengths but also some limitations
to note. The San Diego Population Study is a large multiethnic
population-based study, specifically designed to investigate
lower extremity PAD, with standardized clinic examinations
and assay measurement. However, our study was cross-
sectional in nature; thus we cannot draw definitive conclu-
sions regarding associations of femoral artery atherosclerosis
and declines in physical function over time, especially among
participants with a normal-range ABI. The femoral artery IMT
and plaque measurements were performed with standardized
protocols and quality control measures by trained ultrasound
technicians. Our predominantly healthy older adult population
enabled investigation of how femoral artery atherosclerosis
was related to physical functioning even in participants who
have normal-range ABIs and who are likely in the earlier
stages of the lower-extremity disease process. For some
images and some arterial segments, clear visualization of the
IMT and plaques was difficult. However, we addressed this by
using the far (posterior) artery wall to limit noise and
measurement error for the IMT. We also performed sensitivity
analysis, modeling plaque presence and total number of
plaques with categorization as definite versus probable/no
plaque. We modeled SPS as a perfect score (12) versus less
than a perfect score. However, the modeling of SPS in this
manner was appropriate for a population such as the one
studied here, which is predominantly healthy, and it also aided
in clinically relevant interpretation of the results. Also, one of
our main aims was to identify early changes in physical
function that may result from subclinical lower extremity
atherosclerosis in participants with a normal-range ABI.
In a population-based multiethnic study of older adults, a
greater burden of femoral artery atherosclerosis was associ-
ated with a lower overall SPS, and less favorable performance
on its components, even among participants with a normal-
range ABI. Significant associations were primarily for the
superficial femoral artery, which may play a larger role than the
common femoral artery in reduced physical functioning. Our
study indicates that in early-stage atherosclerosis, femoral
artery changes may detect abnormalities leading to poorer
physical performance earlier in the course of PAD (ie,
subclinical PAD) than those required, which result in a low
ABI (≤0.90), typically considered PAD. While it may be
prohibitive to screen all patients with a normal ABI for femoral
artery atherosclerosis, it could be very beneficial for early
detection in those who have other comorbidities such as type 2
diabetes mellitus or a family history of PAD, and a normal ABI.
Indeed, family history of PAD is strongly associated with PAD.35
Findings also suggest that use of femoral artery atheroscle-
rosis measures may be especially effective and beneficial in
individuals with a normal-range ABI who are likely
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asymptomatic, when detection can lead to earlier intervention
to prevent functional declines and improve quality of life. Early
interventions could range from lifestyle, such as an exercise
program, to pharmacologic, such as initiation or intensifica-
tion of statins. However, additional follow-up studies are first
needed to confirm associations of femoral artery atheroscle-
rosis with declines in physical function over time among those
with a normal-range ABI.
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